ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚÀÇ ¹æ»ç¼± Ä¡·á ½Ã Á¦ÇÑ È£Èí ÁÖ±âÀÇ À¯¿ë¼º Æò°¡
Evaluation of the Usefulness of Restricted Respiratory Period at the Time of Radiotherapy for Non-Small Cell Lung Cancer Patient

´ëÇѹæ»ç¼±Ä¡·áÇÐȸÁö 2012³â 24±Ç 2È£ p.123 ~ p.135

¹Ú¼Ò¿¬(Park So-Yeon) - »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
¾ÈÁ¾È£(Ahn Jong-Ho) - »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
¼­Á¤¹Î(Seo Jeong-Min) - ´ë¿ø´ëÇÐ ¹æ»ç¼±°ú
±è¿µÀÏ(Kim Yung-Il) - »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
±èÁø¸¸(Kim Jin-Man) - »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
ÃÖº´±â(Choi Byeong-Ki) - »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú
ǥȫ·Ä(Pyo Hong-Ryull) - ¼­¿ï»ï¼ºº´¿ø ¹æ»ç¼±Á¾¾çÇаú
¼Û±â¿ø(Song Gi-Won) - »ï¼º¼­¿ïº´¿ø ¹æ»ç¼±Á¾¾çÇаú

Abstract

¸ñ Àû: ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚÀÇ È£Èí Á¶Àý ¹æ»ç¼± Ä¡·á ½Ã È£Èí¿¡ ÀÇÇÑ Á¾¾çÀÇ ¿òÁ÷ÀÓÀ» ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀÌ ÇʼöÀûÀÌ´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼­´Â ÀÚÀ¯È£Èí ÁÖ±â¿Í Á¦ÇÑÈ£Èí Áֱ⸦ °¢°¢ Àû¿ëÇÑ Ä¡·á °èȹÀ» ºñ±³, ºÐ¼®ÇÏ¿© Á¦ÇÑ È£Èí ÁÖ±âÀÇ À¯¿ë¼ºÀ» Æò°¡ÇÏ°íÀÚ ÇÑ´Ù.

´ë»ó ¹× ¹æ¹ý: 2011³â 4¿ùºÎÅÍ 12¿ù±îÁö ºñ¼Ò¼¼Æ÷¼º Æó¾Ï ȯÀÚ 9¸í(tumor n=10)À» ´ë»óÀ¸·Î ȯÀÚ¿¡°Ô Æò¼ÒÀÇ È£ÈíÁֱ⸦ ¹ÙÅÁÀ¸·Î ÃøÁ¤ÇÑ ¡®ÀÚÀ¯È£Èí Áֱ⡯¿Í ÀǵµÀûÀ¸·Î ÁÙÀÎ ¡®Á¦ÇÑÈ£Èí Áֱ⡯¸¦ ¡®½ÅÈ£¸ð´ÏÅÍ-È£Èí(guided-breathing)¡¯¹ýÀ» »ç¿ëÇÏ¿© °¢°¢ÈÆ·ÃÀ» ½Ç½ÃÇÑ ÈÄ RPM°ú 4Â÷¿ø Àü»êÈ­ ´ÜÃþÃÔ¿µ ¸ðÀÇÄ¡·á±â¸¦ ÀÌ¿ëÇØ Ä¡·á°èȹ¿ë 4D CT¸¦ ½Ç½ÃÇÏ¿© ÃÑ 10°³ÀÇ È£Èí À§»ó(respiration phase)º° CT ¿µ»óÀ» ȹµæÇÏ¿´´Ù. °¢ È£Èí ÁÖ±âÀÇ CT ¿µ»ó¿¡ °üÃøÀÚ µÎ ¸íÀÌ °¢°¢ ¼³Á¤ÇÑ À°¾ÈÀû Á¾¾çüÀû(GrossTumor Volume, GTV)°ú ³»ºÎÇ¥ÀûüÀû(Internal Target Volume, ITV)ºÎÇǸ¦ ÃøÁ¤, ºñ±³ÇÏ¿´°í µé¼û(end-inspiration, EI)ÀÎ 0%¿Í ³¯¼û(end-exhalation, EE)ÀÎ 50% À§»ó¿¡¼­ÀÇ center of mass (COM)¸¦ ÃøÁ¤ÇÏ¿© Á¾¾ç ¿òÁ÷ÀÓÀÇ ÁøÆøÀ» ÃøÁ¤Çß´Ù. ¶ÇÇÑ °üÃøÀÚ µÎ¸íÀÌ °¢°¢ µÎ È£Èí Áֱ⸦ Àû¿ëÇÑ Ä¡·á°èȹÀ» ¼ö¸³ÇÏ¿´°í Á¤»ó Æó Æò±Õ¼±·®(mean dose to normal lung, MDTNL)°ú Á¤»ó Æó¿ëÀûÀÇ Á¤»óÁ¶Á÷ÇÕº´ÁõÈ®·ü(normal tissue complication probability, NTCP)À» ºñ±³, ºÐ¼®ÇÏ¿´À¸¸ç ÃøÁ¤µÈ ÀÚ·áÀÇ Á¤·®Àû Æò°¡¸¦À§ÇØ Åë°è ºÐ¼®À» ½Ç½ÃÇß´Ù.

°á °ú: °üÃøÀÚ µÎ ¸íÀÇ ¡®Á¦ÇÑÈ£Èí Áֱ⡯¸¦ Àû¿ëÇÑ Ä¡·á °èȹÀ» ºÐ¼®ÇÑ °á°ú ¡®ÀÚÀ¯È£Èí Áֱ⡯¿¡ ºñÇØ Á¾¾çÀÇ 3D ¹æÇâ ¿òÁ÷ÀÓÀÌ°üÃøÀÚ 1ÀÇ °æ¿ì 38.75%, °üÃøÀÚ 2ÀÇ °æ¿ì 41.10%ÀÇ °¨¼ÒÀ²À» º¸¿´°í GTV¿Í ITVÀÇ ºÎÇǸ¦ ÃøÁ¤, ºñ±³ÇÑ °á°ú GTVÀÇ ºÎÇǴ°üÃøÀÚ 1ÀÇ °æ¿ì 14.96¡¾9.44%, °üÃøÀÚ 2ÀÇ °æ¿ì 19.86¡¾10.62%, ITVÀÇ ºÎÇÇ´Â °üÃøÀÚ 1ÀÇ °æ¿ì 8.91¡¾5.91%, °üÃøÀÚ 2ÀÇ °æ¿ì15.52¡¾9.01%ÀÇ °¨¼ÒÀ²À» º¸¿´À¸¸ç MDTNL°ú NTCP¸¦ ºÐ¼®, ºñ±³ÇÑ °á°ú MDTNLÀº °üÃøÀÚ 1ÀÇ °æ¿ì 3.98¡¾5.62%, °üÃøÀÚ 2ÀÇ°æ¿ì 7.62¡¾10.29%ÀÇ °¨¼ÒÀ²À», NTCPÀÇ °æ¿ì °üÃøÀÚ 1ÀÇ °á°ú 21.70¡¾28.27%, °üÃøÀÚ 2ÀÇ °á°ú 37.83¡¾49.93%ÀÇ °¨¼ÒÀ²À» ³ªÅ¸³Â´Ù. ¶ÇÇÑ µÎ °üÃøÀÚÀÇ °á°ú °ªÀÇ »ó°ü°ü°è¸¦ ºÐ¼®ÇÑ °á°ú ¡®ÀÚÀ¯È£Èí Áֱ⡯¿¡¼­´Â °üÃøÀÚ°£ÀÇ À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌ´Â µ¥ ºñÇØ¡®Á¦ÇÑÈ£Èí Áֱ⡯¿¡¼­´Â °üÃøÀÚ°£ÀÇ Â÷ÀÌ°¡ ¾ø´Â °¨¼ÒÀ²À» º¸¿´´Ù.

°á ·Ð: ¡®ÀÚÀ¯È£Èí Áֱ⡯¿¡ ºñÇØ ¡®Á¦ÇÑÈ£Èí Áֱ⡯¸¦ Àû¿ëÇÑ Ä¡·á °èȹ¿¡¼­ Æò°¡ÀÎÀÚµéÀÇ »ó´ëÀûÀÎ °¨¼Ò¸¦ ³ªÅ¸³»¾î ºñ¼Ò¼¼Æ÷¼ºÆó¾Ï ȯÀÚÀÇ È£Èí Á¶Àý ¹æ»ç¼± Ä¡·á ½Ã ¡®Á¦ÇÑÈ£Èí Áֱ⡯ÀÇ À¯¿ë¼º ¹× Ÿ´ç¼ºÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù.
Purpose: It is essential to minimize the movement of tumor due to respiratory movement at the time of respiration controlled radiotherapy of non-small cell lung cancer patient. Accordingly, this Study aims to evaluate the usefulness of restricted respiratory period by comparing and analyzing the treatment plans that apply free and restricted respiration period respectively.

Materials and Methods: After having conducted training on 9 non-small cell lung cancer patients (tumor n=10) from April to December 2011 by using ¡®signal monitored-breathing (guided- breathing)¡¯ method for the ¡®free respiratory period¡¯ measured on the basis of the regular respiratory period of the patents and ¡®restricted respiratory period¡¯ that was intentionally reduced, total of 10 CT images for each of the respiration phases were acquired by carrying out 4D CT for treatment planning purpose by using RPM and 4-dimensional computed tomography simulator. Visual gross tumor volume (GTV) and internal target volume (ITV) that each of the observer 1 and observer 2 has set were measured and compared on the CT image of each respiratory interval. Moreover, the amplitude of movement of tumor was measured by measuring the center of mass (COM) at the phase of 0% which is the end-inspiration (EI) and at the phase of 50% which is the end-exhalation (EE). In addition, both observers established treatment plan that applied the 2 respiratory periods, and mean dose to normal lung (MDTNL) was compared and analyzed through dose-volume histogram (DVH). Moreover, normal tissue complication probability (NTCP) of the normal lung volume was compared by using dose-volume histogram analysis program (DVH analyzer v.1) and statistical analysis was performed in order to carry out quantitative evaluation of the measured data.

Results: As the result of the analysis of the treatment plan that applied the ¡®restricted respiratory period¡¯ of the observer 1 and observer 2, there was reduction rate of 38.75% in the 3-dimensional direction movement of the tumor in comparison to the ¡®free respiratory period¡¯ in the case of the observer 1, while there reduction rate was 41.10% in the case of the observer 2. The results of measurement and comparison of the volumes, GTV and ITV, there was reduction rate of 14.96¡¾?9.44% for observer 1 and 19.86 ¡¾:10.62% for observer 2 in the case of GTV, while there was reduction rate of 8.91¡¾?5.91% for observer 1 and 15.52¡¾?9.01% for observer 2 in the case of ITV. The results of analysis and comparison of MDTNL and NTCP illustrated the reduction rate of MDTNL 3.98¡¾?5.62% for observer 1 and 7.62¡¾?10.29% for observer 2 in the case of MDTNL, while there was reduction rate of 21.70¡¾z28.27% for observer 1 and 37.83¡¾?49.93% for observer 2 in the case of NTCP. In addition, the results of analysis of correlation between the resultant values of the 2 observers, while there was significant difference between the observers for the ¡®free respiratory period¡¯, there was no significantly different reduction rates between the observers for ¡®restricted respiratory period.

Conclusion: It was possible to verify the usefulness and appropriateness of ¡®restricted respiratory period¡¯ at the time of respiration controlled radiotherapy on non-small cell lung cancer patient as the treatment plan that applied ¡®restricted respiratory period¡¯ illustrated relative reduction in the evaluation factors in comparison to the ¡®free respiratory period.

Å°¿öµå

È£ÈíÁ¶Àý¹æ»ç¼±Ä¡·á, Á¦ÇÑÈ£Èí ÁÖ±â, Á¾¾ç ¿òÁ÷ÀÓ, Á¤»ó Æó ¼±·®, Á¤»óÁ¶Á÷ÇÕº´ÁõÈ®·ü, ºñ¼Ò¼¼Æ÷¼º Æó¾Ï
respiratory control radiation therapy, restricted respiratory period, target mobility, mean dose to normal lung (MDTNL), normal tissue complication probability (NTCP), non small cell lung cancer (NSCLC)
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This study verified the usefulness and appropriateness of ¡®restricted respiratory period¡¯ at the time of respiration controlled radiotherapy on non-small cell lung cancer patient as the treatment plan that applied ¡®restricted respiratory period¡¯ .
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå